Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

Exclusion Criteria

• •Large cell carcinoma and mixed cell lung cancer.
• •Any systemic anti-cancer treatment for NSCLC, including cytotoxic drug therapy, immunotherapy, experimental treatment.
• •Prior treatment with local radiotherapy.
• •Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors).
• •Prior treatment with antilotinib and other antiangiogenic drugs.
• •History of hypersensitivity to any active or inactive ingredient of Penpulimab, Anlotinib or chemotherapy.
• •Patients with multiple factors affecting oral medication (e.g. inability to swallow, chronic diarrhea, and intestinal obstruction, etc.).
• •Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
• •Patients whose tumor has invaded important blood vessels or whose tumor is likely to invade important blood vessels and cause fatal massive hemorrhage during follow-up study.
• •Patients who have had arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism.
• •Pregnant or lactating women.
• •History of neurological or mental disorders, including epilepsy or dementia.